Tenofovir diphosphate in dried blood spots and HIV-1 resistance in South Africa.
Adherence
Dried blood spots
HIV resistance
South Africa
Tenofovir diphosphate
Journal
AIDS research and therapy
ISSN: 1742-6405
Titre abrégé: AIDS Res Ther
Pays: England
ID NLM: 101237921
Informations de publication
Date de publication:
14 09 2023
14 09 2023
Historique:
received:
02
06
2023
accepted:
29
07
2023
medline:
15
9
2023
pubmed:
14
9
2023
entrez:
13
9
2023
Statut:
epublish
Résumé
Suboptimal antiretroviral (ART) adherence can lead to virologic failure with consequent HIV-1 resistance. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a powerful biomarker of cumulative adherence, predictive of future viremia. It has been associated with resistance in Persons With HIV (PWH) in South Africa and the US. We explored the relationship of TFV-DP concentrations with antiretroviral drug resistance at the time of treatment failure in SA. Adult PWH from health clinics in Cape Town, South Africa on efavirenz-based first-line ART containing tenofovir disoproxil fumarate (TDF) with an undetectable (< 50 copies/mL) HIV-1 viral load (VL) were prospectively enrolled in an observational cohort for 12 months. Monthly study visits included blood collection for HIV-1 VL and DBS for TFV-DP. The first confirmed viral breakthrough (VB) > 400 copies/mL triggered HIV-1 genotyping at the subsequent visit. An electronic adherence (EA) device monitored ART adherence in real-time, estimated as a percent for the 30-days prior to VB. Wilcoxon rank sum test was used to compare median [IQR] TFV-DP by genotype outcome. Of 250 individuals, (n = 195, 78% women), 21 experienced VB, with a median of 5 [4;7] months on study, and a median EA of 33.3 [13.3;53.3]%. Demographic characteristics between those with and without VB were similar. Median VL at VB was 4.0 [3.2;4.5] log copies/mL. TFV-DP concentrations trended down towards the VB visit. Median TFV-DP concentrations were significantly higher in those HIV-1 genotype did not amplify due to being virally suppressed at the subsequent visit (n = 10; 380 [227-661] fmol/punch, p = 0.035; EA 45 [24.9; 59.2]%); than in those who were successfully genotyped with evidence of drug resistance (n = 5, 241 [150-247] fmol/punch, EA 20 [6.7;36.7]%) and in individuals who did not have resistance (n = 3, 39.9 [16.6; 93.9] fmol/punch; EA 33.3 [16-38]%). Three genotype collections were not done. Only non-nucleoside reverse transcriptase inhibitor-associated mutations were identified on resistance testing. (K103N, E138K, Y118H). TFV-DP in DBS showed a step-wise inverse relationship with VB and drug resistance, with evidence of low cumulative ART adherence in PWH who developed antiretroviral resistance. Monitoring TFV-DP concentrations could be a valuable tool for predicting future VB and future resistance.
Sections du résumé
BACKGROUND
Suboptimal antiretroviral (ART) adherence can lead to virologic failure with consequent HIV-1 resistance. Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a powerful biomarker of cumulative adherence, predictive of future viremia. It has been associated with resistance in Persons With HIV (PWH) in South Africa and the US. We explored the relationship of TFV-DP concentrations with antiretroviral drug resistance at the time of treatment failure in SA.
METHODS
Adult PWH from health clinics in Cape Town, South Africa on efavirenz-based first-line ART containing tenofovir disoproxil fumarate (TDF) with an undetectable (< 50 copies/mL) HIV-1 viral load (VL) were prospectively enrolled in an observational cohort for 12 months. Monthly study visits included blood collection for HIV-1 VL and DBS for TFV-DP. The first confirmed viral breakthrough (VB) > 400 copies/mL triggered HIV-1 genotyping at the subsequent visit. An electronic adherence (EA) device monitored ART adherence in real-time, estimated as a percent for the 30-days prior to VB. Wilcoxon rank sum test was used to compare median [IQR] TFV-DP by genotype outcome.
RESULTS
Of 250 individuals, (n = 195, 78% women), 21 experienced VB, with a median of 5 [4;7] months on study, and a median EA of 33.3 [13.3;53.3]%. Demographic characteristics between those with and without VB were similar. Median VL at VB was 4.0 [3.2;4.5] log copies/mL. TFV-DP concentrations trended down towards the VB visit. Median TFV-DP concentrations were significantly higher in those HIV-1 genotype did not amplify due to being virally suppressed at the subsequent visit (n = 10; 380 [227-661] fmol/punch, p = 0.035; EA 45 [24.9; 59.2]%); than in those who were successfully genotyped with evidence of drug resistance (n = 5, 241 [150-247] fmol/punch, EA 20 [6.7;36.7]%) and in individuals who did not have resistance (n = 3, 39.9 [16.6; 93.9] fmol/punch; EA 33.3 [16-38]%). Three genotype collections were not done. Only non-nucleoside reverse transcriptase inhibitor-associated mutations were identified on resistance testing. (K103N, E138K, Y118H).
CONCLUSION
TFV-DP in DBS showed a step-wise inverse relationship with VB and drug resistance, with evidence of low cumulative ART adherence in PWH who developed antiretroviral resistance. Monitoring TFV-DP concentrations could be a valuable tool for predicting future VB and future resistance.
Identifiants
pubmed: 37705102
doi: 10.1186/s12981-023-00552-w
pii: 10.1186/s12981-023-00552-w
pmc: PMC10500931
doi:
Substances chimiques
Anti-Retroviral Agents
0
tenofovir diphosphate
0
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
67Subventions
Organisme : NIAID NIH HHS
ID : R01 AI122300
Pays : United States
Informations de copyright
© 2023. BioMed Central Ltd., part of Springer Nature.
Références
J Acquir Immune Defic Syndr. 2015 Dec 15;70(5):495-502
pubmed: 26218411
Clin Infect Dis. 2016 Dec 15;63(12):1661-1667
pubmed: 27660234
HIV Med. 2022 May;23(5):465-473
pubmed: 34704355
J Int AIDS Soc. 2021 Dec;24(12):e25849
pubmed: 34910844
J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219888457
pubmed: 31750768
Ther Adv Infect Dis. 2021 May 14;8:20499361211010596
pubmed: 34035910
Antivir Ther. 2012;17(5):785-92
pubmed: 22414552
AIDS Behav. 2014 Jun;18(6):1133-41
pubmed: 24452497
J Virol. 2002 Sep;76(18):9253-9
pubmed: 12186909
J Acquir Immune Defic Syndr. 2006 Oct 1;43(2):247-8
pubmed: 17003672
Curr HIV/AIDS Rep. 2018 Feb;15(1):49-59
pubmed: 29380227
AIDS Behav. 2013 Jan;17(1):284-97
pubmed: 22407465
J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):386-391
pubmed: 31658181
Cochrane Database Syst Rev. 2022 Jul 25;7:CD013080
pubmed: 35871531
J Antimicrob Chemother. 2018 Jun 1;73(6):1665-1671
pubmed: 29528412
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
J Infect Dis. 2019 Jul 19;220(4):635-642
pubmed: 30942881
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038282
Drug Resist Updat. 2002 Dec;5(6):219-23
pubmed: 12531178
Health Qual Life Outcomes. 2017 May 30;15(1):115
pubmed: 28558805
AIDS. 2022 Jun 1;36(7):933-940
pubmed: 35131960
AIDS Behav. 2010 Dec;14(6):1340-6
pubmed: 20809380
Clin Infect Dis. 2019 Apr 8;68(8):1335-1342
pubmed: 30137238
AIDS Res Hum Retroviruses. 2022 Jun;38(6):455-462
pubmed: 34779228
Curr Opin HIV AIDS. 2012 Mar;7(2):99-105
pubmed: 22227585
BMC Infect Dis. 2019 Sep 5;19(1):775
pubmed: 31488063
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6692-6697
pubmed: 27572401
Res Nurs Health. 2001 Dec;24(6):518-29
pubmed: 11746080
Curr HIV/AIDS Rep. 2020 Aug;17(4):301-314
pubmed: 32424549
Proc Am Control Conf. 2012;2012:4053-4058
pubmed: 25264400